|
|
The
standard dose of Agenerase™ requires individuals
to take large numbers of pills. Norvir™ has been
shown to lengthen the time that Agenerase™ stays
in the blood. In theory, that might mean that Norvir™
can increase the potency of a small amount of Agenerase™
. |
|
Objective
|
To
determine whether the addition of low dose Norvir™
to lower, experimental dose Agenerase™ will be as
effective as the higher, standard dose of Agenerase™
. |
|
|
Volunteers
will be assigned to one of two study groups:
Group
1: Volunteers will receive 1200 mg of Agenerase™
. At least 2 additional anti-HIV medications will be
prescribed.
Group
2: Volunteers will receive 600 mg of Agenerase™
and 100 mg of Norvir™. At least 2 additional anti-HIV
medications will be prescribed.
|
|
Inclusion
Criteria
|
•
Two kinds of volunteers are needed:
- Volunteers
who have taken or are taking anti-HIV medications.
- Volunteers
who have never taken anti-HIV medications before.
•
T-cell count greater than 50
•
HIV+ male or female
•
If female, not pregnant and willing to use contraceptives
for the duration of the study.
|
|
Status
__
|
Enrolling
--
|
For
more information about participating in this study
in the Los Angeles area, please call 310/358.2429
or e-mail Corie Castro at ccastro@aidsresearch.org
|
|
We
encourage participation by women and people of color.
This
ad was reviewed and approved by the AIDS Research Alliance
Institutional Review Board in December, 2000.
|
